Mirtazapina Teva-Ratio (Mirtazapine)

Mirtazapine blocks presynaptic α2‑adrenergic receptors, which increases norepinephrine release, and antagonizes 5‑HT2 and 5‑HT3 serotonin receptors while stimulating 5‑HT1 receptors. This combined action enhances noradrenergic and serotonergic neurotransmission, helping to correct mood imbalances associated with depression.

The appropriate dose of Mirtazapina Teva‑Ratio is determined individually by the prescribing healthcare professional based on the patient’s clinical condition, response to therapy, and tolerability. Dosage adjustments are made according to medical judgment and patient needs.

The safety of mirtazapine in pregnancy and lactation has not been definitively established. Healthcare providers should weigh the potential benefits against possible risks and consider alternative treatments when treating pregnant or nursing individuals.

To place an order, submit an enquiry on the product page at gnhindia.com, specifying the required quantity. GNH India works with hospitals, pharmacies, and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details, and any necessary import documentation.

Mirtazapine differs from selective serotonin reuptake inhibitors (SSRIs) by its dual noradrenergic and serotonergic activity and strong antihistamine effect, which often leads to sedation and weight gain. It may be preferred when patients need a sedating antidepressant or have poor appetite, whereas SSRIs are generally less sedating.

Mirtazapina Teva‑Ratio should be stored at room temperature, below 25 °C, in its original packaging. Keep the product away from moisture, direct sunlight, and excessive heat to maintain its stability and potency.

The medication is taken orally, usually once daily in the evening, with or without food. Patients should follow the prescribing clinician’s instructions regarding timing and whether to swallow the tablet whole or with a small amount of water.

Serious risks include the potential for suicidal thoughts or behaviors, especially early in treatment, agranulocytosis or severe neutropenia, hyponatremia due to SIADH, and rare severe skin reactions such as Stevens‑Johnson syndrome. Prompt medical attention is required if any of these occur.

Mirtazapina Teva‑Ratio is contraindicated in patients who have taken monoamine oxidase inhibitors within the past 14 days, those with known hypersensitivity to mirtazapine, and individuals with severe hepatic impairment where the drug’s safety cannot be assured.